Clinical effect of lentinan combined with DN chemotherapy for non-small cell lung cancer complicated with tuberculosis
Pages: 518-520,554
Year: 2017 Issue: 5
Journal: Oncology Progress
Abstract: Objective To observe the curative effect of lentinan combined with docetaxel and nedaplatin (DN) che-motherapy regimen for non-small cell lung cancer (NSCLC) complicated with tuberculosis, and its impact on pulmonary function and quality of life. Method 84 cases of patients with NSCLC complicated with tuberculosis were retrospective-ly analyzed, and the patients were divided into control group and study group based on their treatment regimens, with 42 cases in each group. The patients in both groups were given DN chemotherapy regimen, and those in study group were ad-ditionally given lentinan. The clinical efficacy, pulmonary function and adverse reactions were compared between two groups, and the quality of life was evaluated using EORTC QLQ-C30 scale. Result The clinical efficiency and clinical benefit rate of study group was 50.0%and 90.5%, respectively, both were higher than those of control group (28.6%and 76.2%, P<0.05). After treatment, the scores of pulmonary function indicators (maximal expiratory flow rate, maximal vol-untary ventilarion and diffusion capacity of carbonmonoxide) of study group were higher than those of control group, the scores of fatigue, nausea and vomiting, dyspnea and diarrhea of study group were lower than those of control group, and the differences were statistically significant (P<0.05). The incidence of nausea/vomiting and diarrhea of study group was 76.2%and 57.1%, respectively, both lower than those of control group (92.9%and 80.9%, P<0.05). Conclusion In the treatment of NSCLC complicated with tuberculosis, the combination therapy of lentinan and DN chemotherapy can im-prove the curative effect, pulmonary function and quality of life, and can reduce the incidence of adverse reactions. It is worthy of clinical application.
Year: 2017 Issue: 5
Journal: Oncology Progress
Abstract: Objective To observe the curative effect of lentinan combined with docetaxel and nedaplatin (DN) che-motherapy regimen for non-small cell lung cancer (NSCLC) complicated with tuberculosis, and its impact on pulmonary function and quality of life. Method 84 cases of patients with NSCLC complicated with tuberculosis were retrospective-ly analyzed, and the patients were divided into control group and study group based on their treatment regimens, with 42 cases in each group. The patients in both groups were given DN chemotherapy regimen, and those in study group were ad-ditionally given lentinan. The clinical efficacy, pulmonary function and adverse reactions were compared between two groups, and the quality of life was evaluated using EORTC QLQ-C30 scale. Result The clinical efficiency and clinical benefit rate of study group was 50.0%and 90.5%, respectively, both were higher than those of control group (28.6%and 76.2%, P<0.05). After treatment, the scores of pulmonary function indicators (maximal expiratory flow rate, maximal vol-untary ventilarion and diffusion capacity of carbonmonoxide) of study group were higher than those of control group, the scores of fatigue, nausea and vomiting, dyspnea and diarrhea of study group were lower than those of control group, and the differences were statistically significant (P<0.05). The incidence of nausea/vomiting and diarrhea of study group was 76.2%and 57.1%, respectively, both lower than those of control group (92.9%and 80.9%, P<0.05). Conclusion In the treatment of NSCLC complicated with tuberculosis, the combination therapy of lentinan and DN chemotherapy can im-prove the curative effect, pulmonary function and quality of life, and can reduce the incidence of adverse reactions. It is worthy of clinical application.
Related Articles